These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25293518)

  • 21. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR tyrosine kinase inhibitor Almonertinib induces apoptosis and autophagy mediated by reactive oxygen species in non-small cell lung cancer cells.
    Ge X; Zhang Y; Huang F; Wu Y; Pang J; Li X; Fan F; Liu H; Li S
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S49-S62. PubMed ID: 34219533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.
    Eimer S; Belaud-Rotureau MA; Airiau K; Jeanneteau M; Laharanne E; Véron N; Vital A; Loiseau H; Merlio JP; Belloc F
    Cancer Biol Ther; 2011 Jun; 11(12):1017-27. PubMed ID: 21508666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Lebègue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer.
    Chmielecki J; Pao W
    Clin Cancer Res; 2010 Nov; 16(22):5371-3. PubMed ID: 21062927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.
    Li X; Lu Y; Pan T; Fan Z
    Autophagy; 2010 Nov; 6(8):1066-77. PubMed ID: 20864811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
    Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
    J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
    Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
    Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
    To KKW; Wu WKK; Loong HHF
    Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.
    Koustas E; Karamouzis MV; Mihailidou C; Schizas D; Papavassiliou AG
    Cancer Lett; 2017 Jun; 396():94-102. PubMed ID: 28323034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer.
    Kumar M; Joshi G; Chatterjee J; Kumar R
    Curr Top Med Chem; 2020; 20(12):1105-1123. PubMed ID: 32031073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells.
    Kang M; Lee KH; Lee HS; Jeong CW; Kwak C; Kim HH; Ku JH
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2.
    Lv XX; Zheng XY; Yu JJ; Ma HR; Hua C; Gao RT
    Cancer Med; 2020 Feb; 9(3):1131-1140. PubMed ID: 31823521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.